78081-87-5

Usage

Uses

Used in Peptide Synthesis:
FMOC-LYS(FMOC)-OH is used as a protected amino acid in the synthesis of branched peptides. The Fmoc protecting group allows for selective deprotection and coupling of amino acids, enabling the formation of complex peptide structures.
Used in Pharmaceutical Industry:
FMOC-LYS(FMOC)-OH is used in the synthesis of [Lys8]-oxytocin related dendrimers, which have been shown to be functionally active in vitro on human oxytocin receptors. These dendrimers have also demonstrated potent inhibition of colonic nociceptors in a mouse model of chronic abdominal pain, indicating their potential use in the development of therapeutic agents for pain management and other oxytocin-related conditions.

InChI:InChI=1/C36H34N2O6/c39-34(40)33(38-36(42)44-22-32-29-17-7-3-13-25(29)26-14-4-8-18-30(26)32)19-9-10-20-37-35(41)43-21-31-27-15-5-1-11-23(27)24-12-2-6-16-28(24)31/h1-8,11-18,31-33H,9-10,19-22H2,(H,37,41)(H,38,42)(H,39,40)/t33-/m0/s1

Upstream product

• 657-27-2 L-Lysine hydrochloride 
• 82911-69-1 N-(9H-fluoren-2-ylmethoxycarbonyloxy)succinimide 
• 56-87-1 L-lysine 
• 28920-43-6 (fluorenylmethoxy)carbonyl chloride 
• 71989-26-9 Fmoc-Lys(tert-butoxycarbonyl) 

Downstream Products

• 745795-93-1 N-(N^α,N^ε-bis-Fmoc-L-Lys)-O-(4,4'-dimethoxytrityl)-O'-(tert-butyldimethylsilyl)diethanolamine 
• 1311274-06-2 C₅₆H₇₈N₁₀O₁₂ 
• 1315576-93-2 C₇₀H₁₀₅N₁₆O₂₀PS₂ 
• 1315576-94-3 C₈₅H₁₂₇N₂₀O₂₂PS₂ 
• 1315576-99-8 C₉₆H₁₄₄N₃₀O₁₇ 
• 1315576-96-5 C₆₂H₈₆N₁₀O₁₂ 

Relevant academic research and scientific papers

Amino Acids Bearing Aromatic or Heteroaromatic Substituents as a New Class of Ligands for the Lysosomal Sialic Acid Transporter Sialin

Sialin, encoded by the SLC17A5 gene, is a lysosomal sialic acid transporter defective in Salla disease, a rare inherited leukodystrophy. It also enables metabolic incorporation of exogenous sialic acids, leading to autoantibodies against N-glycolylneuraminic acid in humans. Here, we identified a novel class of human sialin ligands by virtual screening and structure-activity relationship studies. The ligand scaffold is characterized by an amino acid backbone with a free carboxylate, an N-linked aromatic or heteroaromatic substituent, and a hydrophobic side chain. The most potent compound, 45 (LSP12-3129), inhibited N-acetylneuraminic acid 1 (Neu5Ac) transport in a non-competitive manner with IC50 ≈ 2.5 μM, a value 400-fold lower than the KM for Neu5Ac. In vitro and molecular docking studies attributed the non-competitive character to selective inhibitor binding to the Neu5Ac site in a cytosol-facing conformation. Moreover, compound 45 rescued the trafficking defect of the pathogenic mutant (R39C) causing Salla disease. This new class of cell-permeant inhibitors provides tools to investigate the physiological roles of sialin and help develop pharmacological chaperones for Salla disease.

New conjugates of antitumor antibiotic doxorubicin with water-soluble galactomannan: Synthesis and biological activity

New water-soluble conjugates in the form of Schiff bases (DGM-1 and DGM-2) were prepared by the interaction of water-soluble periodate-oxidized galactomannan with doxorubicin or N-(L-lysyl)doxorubicin, respectively. The water-soluble galactomannan (DAVANAT, a commercial product of Pro-Pharmaceuticals company) was obtained by partial acidic hydrolysis of high-molecular-mass galactomannan from Cyamopsis tetragonoloba (guar gum) seeds. The conjugate stability was studied in aqueous solutions. The DGM-1 anti-proliferative activity was comparable with that of doxorubicin on three models: cell lines of murine melanoma B16-F1 and human breast cancer MCF-7 (HTB-22) and human colon cancer HT-29 (HTB-38). DGM-2 was poorly active in all the three tests. DGM-1 can thus be regarded as a high-molecular-mass depot form of doxorubicin.

ERYTHROPOIETIN RECEPTOR PEPTIDE FORMULATIONS AND USES

The present invention relates to peptide compounds that are agonists of the erythropoietin receptor (EPO-R). The invention also relates to therapeutic methods using such peptide compounds to treat disorders associated with insufficient or defective red blood cell production. Pharmaceutical compositions, which comprise the peptide compounds of the invention, and dosages are also provided.

Amino acid derivatives as HIV aspartyl protease inhibitors

The present invention relates to a class of amino acid derivatives with HIV aspartyl protease inhibitory properties.